Discovery and Optimization of Novel Compounds Targeting Programmed Ribosomal Frameshifting in RNA Viruses
Direct intralesional mTOR inhibition for targeted treatment of sporadic and syndromic venous and lymphatic malformations
Target Site Blocker (TSB) of the IL-17A-miR466I-3p iInteraction Prevents Progressive and Relapsing Remitting EAE